Trumenba 60 ug/.5mL

Trumenba 60 ug/0.5mL is a meningococcal group B vaccine designed to help prevent infections caused by Neisseria meningitidis serogroup B. This intramuscular injection is suitable for individuals at risk of meningococcal disease.

Trumenba is used to protect against meningococcal group B bacteria, which can cause serious infections like meningitis and sepsis. This vaccine is typically administered to individuals aged 10 to 25 years who are at increased risk of exposure to the bacteria. The vaccine works by stimulating the body's immune response to develop protection against the meningococcal group B strain.

Common effects of Trumenba may include mild to moderate pain, redness, or swelling at the injection site. Some individuals may experience fatigue, headache, muscle pain, or fever following vaccination. These effects are usually temporary and resolve within a few days.

Trumenba should be administered by healthcare professionals trained in vaccination procedures. Individuals with a history of severe allergic reactions to any component of the vaccine should avoid it. It is important to inform the healthcare provider about any current illnesses or allergies before receiving the vaccine.

Trumenba may interact with certain medications or other vaccines. It is advisable to discuss all current medications, including over-the-counter drugs and supplements, with a healthcare provider before vaccination. Alcohol consumption should be avoided immediately before and after receiving the vaccine to minimize potential side effects.